This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

Back

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Topics Sessions Videos Previous meetings

MPN - 318

Characterization of Symptoms After Immediate Transition From Ruxolitinib to Momelotinib in Patients With Myelofibrosis: Post-Hoc Analyses of the Phase 3 SIMPLIFY-1 and SIMPLIFY-2 Trials

Preview of Characterization of Symptoms After Immediate Transition From Ruxolitinib to Momelotinib in Patients With Myelofibrosis: Post-Hoc Analyses of the Phase 3 SIMPLIFY-1 and SIMPLIFY-2 Trials

View Poster Contact Presenter

Poster Presenter

Pankit J Vachhani

Authors

Pankit J Vachhani

Part of Topic

Myeloproliferative Neoplasms (MPN)

Characterization of symptoms after immediate transition from ruxolitinib to momelotinib in patients with myelofibrosis: post hoc analyses of the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials

Other ePosters in

Topic

MPN - 032The Clinical, Prognostic, and Therapeutic Implications of Mutational Pro...

MPN - 034Real-World Epidemiology of Mast Cell Sarcoma: Evidence from a National C...

MPN - 088Survival Outcomes and Racial Disparities in Adolescent and Young Adult C...

MPN - 099Restore-PV: A Phase 2 Open-Label Study Evaluating the Safety and Efficac...

MPN - 1016Burden and Outcomes of Arterial and Venous Thrombosis in Essential Throm...

ePosters in

Topics

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)